<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151930</url>
  </required_header>
  <id_info>
    <org_study_id>SCB01A-01-B</org_study_id>
    <nct_id>NCT01151930</nct_id>
  </id_info>
  <brief_title>Long-Term Compassionate Use Study for Continued Administration of SCB01A-01</brief_title>
  <official_title>Long-Term Compassionate Use Study for Continued Administration of SCB01A In Subjects Who Completed Treatment With SCB01A in the Previous Protocol # SCB01A-01</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SynCore Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SynCore Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to characterize the safety profile of long-term exposure to SCB01A
      when administered to cancer subjects with advanced solid tumors. Furthermore, the efficacy
      profile will also be explored in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a companion study to the protocol SCB01A-01 intended to provide long-term continued
      administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is
      an open-label, single-arm study of SCB01A in subjects who have completed at least one cycles
      of treatment under the SCB01A-01 protocol.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Expanded Access</study_type>
  <condition>Malignant Solid Tumour</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCB01A</intervention_name>
    <description>This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who completed protocol SCB01A-01 and exhibited a favorable response or had no
        clinical evidence of disease progression (i.e. stable disease, partial response or
        complete response).

        Exclusion Criteria:

        Study participants meeting any of the following criteria will be excluded from enrollment:

          1. Unwilling or unable to provide informed consent.

          2. Unwilling or unable to comply with the requirements of the protocol.

          3. Has unresolved toxicities from previous SCB01A-01 protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mukesh Kumar, PhD</last_name>
    <phone>(240) 750-4893</phone>
    <email>mukeshk@amarexcro.com</email>
  </overall_contact>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 9, 2015</lastchanged_date>
  <firstreceived_date>June 23, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumor failed with standard therapy</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
